Drug intelligence / Profile preview

si-LRP11#1

Development stage: Preclinical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

si-LRP11#1 is a small interfering RNA (siRNA) designed to specifically silence the expression of Low-density lipoprotein receptor-related protein 11 (LRP11). LRP11 is a transmembrane protein and a member of the LDL receptor family that has been identified as a potential prognostic biomarker and a driver of immune suppression in lung adenocarcinoma (LUAD). Research indicates that high LRP11 expression correlates with poor clinical outcomes and an immunosuppressive tumor microenvironment. si-LRP11#1 is utilized in preclinical research to investigate the functional consequences of LRP11 knockdown, including its effects on tumor cell proliferation, RNA splicing, and immune cell infiltration. By degrading LRP11 mRNA, this siRNA construct aims to validate LRP11 as a therapeutic target for non-small cell lung cancer.

Other names: LRP11 siRNA #1siRNA targeting LRP11

Targets

LRP11 (Low-density lipoprotein receptor-related protein 11)

Beyond the preview

Go deeper on si-LRP11#1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on si-LRP11#1.

Explore the full profile